Fidasimtamab

Fidasimtamab binds to purified human PD-1 and Her2 proteins with high affinity, with K_D values of 1.17 × 10^-9 M and 3.55 × 10^-10 M, respectively^[1].
Fidasimtamab (600 nM; 30 min at 4 °C) induces a 24.10% association rate between N87 gastric cancer cells and activated human T cells^[1].
Fidasimtamab (serial dilutions; 3 d) dose-dependently activates human CD4⁺ T cells in an MLR assay, inducing secretion of IFNγ and IL-2 with potency comparable to the parental anti-PD-1 antibody^[1].
Fidasimtamab (600 nM; 24 h) significantly enhances T cell-mediated cytotoxicity against N87 and SNU-216 Her2-positive gastric cancer cells, as measured by increased LDH release^[1].
Fidasimtamab (600 nM; 6 h) induces pyroptosis in N87 and SNU-216 Her2-positive gastric cancer cells in the presence of activated T cells, and increases IL-18 secretion by 24 h, via cleavage of GSDMB to its active N-terminal fragment^[1].
Fidasimtamab (serial dilutions; 4 h at 37 °C) exhibits potent ADCC activity against N87 Her2-positive gastric cancer cells when incubated with human NK cells^[1].
Fidasimtamab (600 nM; 24 h) induces a 2-3 fold increase in cell death in PDXO-1 Her2-positive gastric cancer organoids in the presence of T cells, and promotes association between T cells and organoids^[1].
Conditioned media from Her2-positive gastric cancer cell-T cell cocultures treated with Fidasimtamab (600 nM; 24 h) activates human CD8⁺ T cells, increasing CD25 expression and enhancing IFNγ secretion^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.